Genelux Corporation is a late stage biopharmaceutical company focused on developing oncolytic viral immunotherapies. The company targets patients with aggressive and difficult to treat tumor types. Its lead product candidate Olvi Vec is a proprietary modified strain of the vaccinia virus VACV. VACV is a stable DNA virus with large engineering capacity. Genelux uses its proprietary CHOICE discovery platform to select and engineer oncolytic VACV candidates. The platform has generated an extensive library of isolated and engineered oncolytic VACv immunotherapeutic product candidates. These candidates show potential utility in multiple tumor types. They can be used in monotherapy or combination therapy settings. Administration routes include regional local and systemic methods such as intraperitoneal or intravenous delivery. Olvi Vec is designed to selectively kill tumor cells and induce a robust immune response against patient specific tumor neoantigens. Importantly while the same virus product is given to different patients the immune response is expected to be specific to each patient's unique neoantigens.

Genelux currently has no approved products for sale so it does not generate revenue from product sales. The company's revenue comes from licensing agreements and milestone payments. In September 2021 Genelux entered into a license agreement with Newsoara BioPharma Co Ltd. Under this agreement Genelux received an upfront payment of five million dollars. In October 2025 Newsoara assigned its rights to an affiliate but the agreement terms remained. Genelux has also received a milestone payment of six million dollars from Newsoara. Newsoara is obligated to pay additional development and commercial milestone payments up to one hundred sixty point five million dollars in the aggregate. These payments occur upon achieving specific regulatory and commercial milestones. Royalties on net sales of licensed products will be paid in the mid single digit to mid teens percentage range. The license grants Newsoara exclusive rights to research develop commercialize or exploit Olvi Vec in China Taiwan Hong Kong and Macau for all human diagnostic prophylactic and therapeutic uses.

Genelux operates in the competitive landscape of cancer immunotherapy particularly oncolytic viral therapies. Key competitors for ovarian cancer treatments include Abbvie with ELAHERE Eisai with HEXALEN Roche Genentech with AVASTIN Merck with KEYTRUDA GSK with ZEJULA Astra Zeneca with LYNPARZA and others. For non small cell lung cancer competitors include Roche Genentech Merck Astra Zeneca Novartis Pfizer Johnson and Johnson Eli Lilly and Bristol Myers Squibb. For small cell lung cancer competitors include Amgen Roche Genentech Merck Astra Zeneca and Bristol Myers Squibb. Genelux competitive advantages stem from its advanced clinical progress. Olvi Vec is further along in development than many competing oncolytic virus candidates. The company's CHOICE platform has produced over five hundred different VACV based versions. These versions incorporate more than one hundred ten transgenes with diverse engineered properties. Properties include immune modulatory and tumor cell killing characteristics. Genelux maintains current good manufacturing practice c G M P facilities in San Diego California. This internal capability supports clinical trial material production and future commercial needs. The off the shelf nature of its immunotherapies allows for standardized dosing while enabling patient specific immune responses.

Genelux serves patients with specific cancer indications through its clinical trial programs. The company is currently evaluating Olvi Vec in three active clinical trials. A Phase three registrational trial called On Prime GOG 3076 is underway in the United States for platinum resistant refractory ovarian cancer patients. A Phase two trial called VIRO 25 is being conducted in the United States for recurrent non small cell lung cancer patients. A Phase one b two trial is active in China in collaboration with Newsoara for recurrent small cell lung cancer patients. Beyond these indications preclinical data suggests activity against additional cancer types. These include blood cancers such as leukemia and lymphoma breast cancer colon cancer kidney cancer prostate cancer and skin cancer including melanoma. Genelux does not yet have commercial customers as no products have received regulatory approval for sale. All interactions with patients occur within the context of clinical studies. The company collaborates with Newsoara for patient recruitment and trial conduct in China Hong Kong Taiwan and Macau. In the United States Genelux works with clinical sites and investigators to enroll patients in its trials.